Need Help?
Copied to clipboard!

IMCgp100-102 T cell fitness RNAseq

ImmTACs are bispecific T cell engagers that bind specific peptide-HLA complexes on the surface of cancer cells and redirect T cell cytotoxicity. Since ImmTAC treatment drives peripheral T cell migration into tumors, we hypothesized that pre-treatment blood T cell phenotype may influence clinical outcomes. In a phase 2 study of tebentafusp, a gp100-targeted ImmTAC approved for metastatic uveal melanoma (mUM), we identified a pre-treatment blood T cell fitness gene signature correlated with naïve and memory T cells. On tebentafusp, patients with above-median signature expression showed significantly greater tumor T cell influx, reduced tumor proliferation genes and greater clinical benefit, which was independent of prognostic variables in multivariate analysis. This association was replicated in independent mUM patients treated with brenetafusp, a PRAME-targeting ImmTAC. These findings provide mechanistic insights into T cell engagers and highlight the critical role of blood naïve and memory T cells in anti-tumor activity, with potential implications for adoptive cell therapy.

Cite

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD50000003297 Illumina NovaSeq X 137